AnaptysBio (ANAB) has been removed from several Russell indices, including the Russell Microcap Index and Russell 3000E suite. This is a technical change that can reshape trading flows without reflecting new operational developments.
See our latest analysis for AnaptysBio.
Over the past year AnaptysBio has combined short term swings with very strong longer term gains, with the share price delivering a 30 day share price return of 25.91% and a 1 year total shareholder return above 300%, even as the latest index removals and recent 1 day and 7 day share price declines signal some cooling in near term momentum.
If this kind of sharp move has you thinking about what else is out there, it could be a good moment to look at other healthcare related AI opportunities through the 40 healthcare AI stocks.
The latest pullback after AnaptysBio’s index exits sits awkwardly next to its very strong 1 year return and improving revenue and net income trends, so are you looking at a reset in sentiment or a mismatch with the fundamentals?
Most Popular Narrative: 29.5% Undervalued
AnaptysBio’s latest close of $63.42 sits well below the $90 fair value implied by the most followed narrative, which leans heavily on royalty economics and legal optionality.
TLDR: ANAB has a scaling and rising royalty stream, one up and coming new royalty, a loan that dies in 2027 which will result in a doubling of revenue, and a lawsuit that could soon double the value of the stock.
Royalties as a backstop plus a litigation? Yeah, let’s get into it.
Read the complete narrative. Read the complete narrative.
Curious how a focused royalty model, an upcoming loan runoff, and a high stakes legal case combine into a single $90 fair value story? According to TripleS, the narrative leans on rapidly building royalty inflows, expectations around future profitability, and how any litigation outcome could change the cash flow picture. The real swing factor is how those cash flows are discounted, not just where AnaptysBio trades today.
Result: Fair Value of $90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, AnaptysBio’s royalty heavy story still faces real risks, including litigation outcomes that differ from expectations and future product sales that fall short of current assumptions.
Find out about the key risks to this AnaptysBio narrative.
Next Steps
If this mix of strong gains and active risks around AnaptysBio has you thinking, take a moment now to weigh both sides and test your own thesis against the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond AnaptysBio?
If AnaptysBio has sharpened your thinking, do not stop here. Widening your watchlist now could be the difference between spotting the next move and missing it.
- Target companies that combine quality and value by reviewing our list of 44 high quality undervalued stocks before they attract broader attention.
- Strengthen your downside protection by focusing on businesses highlighted in the 73 resilient stocks with low risk scores, built around resilience and more measured risk profiles.
- Search for tomorrow's potential standouts early by working through the screener containing 18 high quality undiscovered gems, where strong fundamentals have not yet met widespread recognition.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com